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Summary The significant increase in the use of antifungal agents, both for the treatment of
candidiasis and invasive aspergillosis and as azole fungicides in agricultural crop
protection has resulted in the emergence of resistant clinical isolates, particularly to
triazoles and echinocandins. Notably, among isolates that were primarily sensitive to
fluconazole such as Candida parapsilosis and Candida tropicalis have witnessed an
emerging resistance development. Also for echinocandins, the occurrence of Candida
isolates with lower susceptibility to these drugs has been reported, which is possibly
due to its broad clinical use. Triazole resistance among Aspergillus fumigatus and
other Aspergillus species is commonly found in European and Asian countries. Speci-
fic mutations are associated with azole resistance in A. fumigatus and these muta-
tions are now reported globally from six continents. Therefore, we highlight the
need to conduct antifungal resistance surveillance studies using clinical isolates of
Candida and Aspergillus in different geographical regions and monitoring of the infec-
tion rates in distinct population groups for early detection of resistance to these
drugs and implementation of efficient policies for infection control and treatment.
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Introduction
In recent decades, there has been a substantial
increase in the occurrence of invasive fungal infections
(IFIs) due to Candida and Aspergillus in tertiary
hospitals throughout the world.1–3 Despite the large
geographical variability in their incidence rates, IFIs
have undoubtedly become very important worldwide,
particularly among critically ill patients, those with
degenerative or neoplastic diseases and in patients
with organ transplantation.3–5 Given the difficulties in
diagnosing IFIs due to Candida and Aspergillus and
their high mortality rates, prevention strategies and
empirical antifungal therapies have been increasingly
used in different risk groups.2,6–9
In addition the use of antifungal drugs has drasti-
cally increased in medical centres throughout the
world although this increase is not always compatible
with good clinical practice. In fact, some authors have
reported a large number of inappropriate prescriptions
of antifungal drugs even in teaching hospitals, a factor
that increases not only cost and the risk of toxicity
but also the possibility of resistance development to
antifungal agents.10–13 Concurrent with the global
increased consumption of antifungal drugs, there has
been an increase in the number of reported cases of
resistance to different therapeutic antifungal classes
among Candida and Aspergillus species. The present
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review will discuss various antifungal resistance pat-
terns that have emerged in these two most important
fungal pathogens and will also update about the risk
factors and epidemiology of associated fungal
infections.
Epidemiology of triazole resistance in
Candida spp. and Aspergillus spp.
In IFI involving Candida, the gradual use of fluconazole
and other triazoles in therapeutic regimens for prophy-
laxis, empirical therapy and diagnostic-driven therapy
has led to the development of selective pressure with
the emergence of less sensitive species and secondary
resistance among isolates primarily sensitive to these
drugs.14 At first, different medical centres worldwide
reported the increase in infections due to Candida glab-
rata and C. krusei among patients previously exposed
to triazoles. At present, C. glabrata accounts for
18.1%–40.7% of the cases of candidaemia in the US
and 8.5%–31.0% in Europe.15–27 Until 2005, epidemi-
ological studies conducted in Brazil reported a low
frequency (<5%) of candidaemia due to C. glabrata.
Recently, consistent with the epidemiology in the
northern hemisphere, a substantial increase in cases of
fungaemia due to C. glabrata has also been observed in
Brazil. In fact, C. glabrata has accounted for
11.2%–13.1% of the reported cases of candidaemia in
different regions of Brazil.28–30 The same phenomenon
was recently reported in Saudi Arabia by Omrani et al.
[31]. According to these authors, the proportion of C.
glabrata has significantly increased between January
2003 and December 2012.
Candidaemia surveillance in six countries in Asia
namely China, Hong Kong, India, Singapore, Taiwan
and Thailand reported C. albicans (41.3%) as the most
common species.32 Among non-albicans Candida species
C. tropicalis (25.4%) was followed by C. glabrata
(13.9%) and C. parapsilosis (12.1%).32–34 Although the
relative distributions of Candida species varied among
the countries, the proportion of C. tropicalis among
blood isolates was higher in tropical areas (India,
Thailand and Singapore) than other geographical
regions. Candida parapsilosis accounted for 33% of
candidaemia cases in one Indian hospital, 26% in a
Chinese hospital and 14% in a Taiwanese hospital.32
However C. glabrata and C. krusei contributed to 26%
and 12.2% candidaemia cases in tropical countries
(China, India and Singapore).32 Although, most of the
Indian studies demonstrate C. albicans as a predomi-
nant yeast causing invasive candidiasis, nosocomial C.
tropicalis candidaemia ranged from 67% to 90% in
some Indian hospitals.34,35 In Qatar, a retrospective
analysis covering the period from January 2004 to
December 2010 identified 201 episodes of
candidaemia, of which 66.2% was due to non-albicans
Candida species.36 Similar data were obtained in the
United Arab Emirates. In this study, non-albicans
Candida species occurred more frequently than C. albi-
cans in adults (67%), haematological malignancy
patients (58%) and in cases with break through candi-
daemia (83%).37
First described in Japan in 2009, C. auris is increas-
ingly encountered from cases of candidaemia especially
from the Indian subcontinent.38–41 These findings rep-
resent the beginning of an epidemiological shift which
is different from Western countries where the increase
in uncommon Candida species, as C. kefyr and C. lusita-
niae, is likely due to broad use of echinocandins.42
A second epidemiological change, first described in
developed countries, was the increasing occurrence of
fluconazole resistance among isolates of the C. parap-
silosis complex and C. tropicalis. Recent studies that
performed susceptibility tests using reference methods
reported variations in resistance rates among C. parap-
silosis isolates of 3.4%–7.5% in the US and 0%–6% in
Europe.17,18,22,28,43 For C. tropicalis, these rates
were 2.4%–9% in the US and 1.7%–22.0% in
Europe.17,18,20–22,26,28,43 Although infrequent, this
phenomenon has been documented in some South
American countries, as shown in Table 1. In Brazil,
the rates of fluconazole dose-dependent susceptibility
and/or resistance in C. tropicalis and C. parapsilosis are
0%–26.8% and 0%–26.9% respectively. Recently,
Pinhati et al. [44] reported a candidaemia outbreak
due to fluconazole-resistant C. parapsilosis in patients
admitted to intensive care units (ICUs) and Souza et al.
[45] reported mutations associated with this
resistance.
Conceptually, the azole resistance phenotype in
Candida spp. results from the combination of more
than one resistance mechanism.14 Table 2 summarises
the major mechanisms of resistance to this class of
antifungal drugs.
In IFI involving Aspergillus, two phenomena associ-
ated with resistance to antifungal agents were
described: (i) increase in the number of infections due
to non-Aspergillus fumigatus, including emerging spe-
cies primarily resistant to triazoles and eventually to
amphotericin B; and (ii) occurrence of secondary azole
resistance in A. fumigatus isolates. Table 3 summarises
the major species of non-A. fumigatus and those
belonging to the section Fumigati associated with the
phenotype of resistance to the main antifungal agents
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commonly used in clinical practice.46–49 The rate of
infection due to emerging species of Aspergillus is not
fully known because only a few case series have
performed accurate molecular identification, such as
DNA sequencing of Aspergillus at the species level.
However, there are a substantial number of case series
on A. flavus, A. lentulus and A. terreus.50–52 Primary
resistance to amphotericin B (AMB) is well known in
A. terreus, however, in a recent study by Kathuria
et al. [52] low AMB minimum inhibitory concentra-
tion (MIC) (range 0.5–1 mg/L) in 8% of Indian A. ter-
reus isolates were observed. Furthermore, in some
isolates of A. flavus and A. ustus also amphotericin B
resistance was reported.53–55 More recently, this phe-
nomenon has been demonstrated in several species of
the section Fumigati, including A. fumigatiaffinis and A.
lentulus.44,46,48,49,56
Secondary azole resistance in Aspergillus has been
well documented among isolates of A. fumigatus.12,57
Acquired azole resistance has been reported also in A.
flavus and A. terreus, although there is no evidence of
developing acquired resistance to other antimycotic
drugs in other species of this genus.46,48,56,58,59
Table 4 summarises the key studies that determined
the rates of azole resistance in clinical isolates of A.
fumigatus. The resistance rate varied between 0.6%
Table 1 Distribution of Candida species and epidemiology of fluconazole resistance in Latin America.
Countries Author [Reference]
Number of
centres
Number of
isolates
Species distribution1 (%) DDS/Resistance to FCZ2 (%)
Ca Ct Cp Cgla Ck Ca Ct Cp Cgla Ck
Latin
America
Nucci et al. [290] 21 672 37.6 17.6 26.5 6.3 2.7 0.4 0 1.1 100 100
Argentina Cordoba et al. [291] 41 457 38.4 15.4 26 4.33 0.5 0 4.2 2.5 20 ND
Chile Silva et al. [292] 13 130 47 14 21 3 1 0 7 4 33 100
Venezuela Dolande et al. [293] 6 154 46.7 19 6 9.2 2.7 7.4 12.9 10 43.4 96
Colombia Maldonado et al. [294] 15 300 48.3 22.3 15 6.7 2.7 7.6 10.3 24.4 100 100
Mexico Corzo-Leon et al. [295] 2 74 46 26 5 13.5 5 0 0 0 11 ND
Brazil Aquino et al. [296] 1 131 45 15.3 24.4 6.9 4.6 0 0 0 45 100
Brazil Colombo et al. [297] 11 712 40.9 20.9 20.5 4.9 1.1 0.3 0 0 6 37.5
Brazil Bruder-Nascimento
et al. [298]
1 212 33 17.9 31.1 11.8 0 7.1 18.4 1.5 68 ND
Brazil Colombo et al. [29] 9 300 34 24 26 7 3 0 3 0 64 100
Brazil Santos et al. [299] 1 422 35.7 9.71 46.6 3.5 0.9 9.9 26.8 7.1 100 100
Brazil da Costa et al. [300] 1 93 28.7 30.5 24.1 8.3 1.8 3.7 3.2 26.9 0 ND
1Ca, C. albicans; Cd, C. dubliniensis; Ct, C. tropicalis; Cgla, C. glabrata; Cp, C. parapsilosis; Ck, C. krusei; Cgui, C. guilliermondii; FCZ, flucona-
zole; DDS, dose-dependent susceptibility; ND, not determined.
2Rates of DDS/Resistance to FCZ reflects the breakpoints available in that particularly period.
Table 2 Mechanisms of azole resistance in different Candida species.
Mechanism Due to: Result
Occurrence in Candida species1
Ca Cd Ct Cgla Cp Ck
Decrease in the
intracellular concentration
of the target enzyme
- Expression of
ABC transporters
Drug efflux ++ + + ++ ++ ++
- Expression of
MF transporters
++ ++ + + ++ ND
Changes in the drug target Mutations in the
ERG11 gene
Decreased affinity
of the target enzyme
for the azole
++ ++ ++ + ++ ++
Increased production of
lanosterol 14a-demethylase
Multiple factors2 Increased synthesis
of ergosterol
++ ++ ++ ++ ++ ++
1Ca, C. albicans; Cd, C. dubliniensis; Ct, C. tropicalis; Cgla, C. glabrata; Cp, C. parapsilosis; Ck, C. krusei; +, mechanism not yet observed in
clinical isolates; ++, mechanism observed in clinical isolates; ND, mechanism not yet described.
2gene duplication, mutations in the promoter gene or mutations in the gene encoding the target enzyme.
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and 29.6%, and the lowest rate was observed in iso-
lates from the US, where resistance was <1% and
mutations in the CYP51A are rare.12,60,61 Although
triazole resistance is still considered unusual, with
rates of <5% in many countries, azole resistance in A.
fumigatus seems to be increasing in several European
countries, and high rates have been observed primar-
ily in medical centres in Denmark (4.5%), France
(0.8%–8%) and UK (6%–27%).47,62–67 In these coun-
tries, particularly in the UK (specifically in Manch-
ester), high resistance rates (6%–27%) have been
reported among patients with chronic cavitary
aspergillosis who used triazoles for long periods.68,69
To find the proper empirical treatment of invasive
aspergillosis in areas with a high rate of azole resis-
tance is challenging especially in patients with chronic
pulmonary aspergillosis.12,70
A second epidemiological model of the development
of triazole resistance in A. fumigatus has been described
in the Netherlands, where the rates of resistance to
these drugs vary between 1.7% and 30% in patients
not previously exposed to antifungal therapy, thus
suggesting a possible environmental route for the
development of triazole resistance.67,71–75 An epidemi-
ological study conducted in Japan involving 196
clinical isolates reported that 11.2% of the isolates
were resistant to triazoles.76
In Brazil, only two studies reported the prevalence
and rates of triazole resistance among emerging
species of non-A. fumigatus. These studies reported
higher MIC values to these drugs among isolates of A.
calidoustus, A. clavatus, A. tamarii, A. nomius, A. ochra-
ceus and A. terreus.54,77
The rate of azole resistance in clinical A. fumigatus
isolates in India was found to be 1.7%–1.9%.57,78–80
However, in China the ARTEMIS global sentinel
surveillance programme demonstrated a pan-azole-
resistant phenotype in 27.5% of A. fumigatus iso-
lates.81 In contrast, Japan reported 5.2% azole-resis-
tant A. fumigatus isolates.76,82 A similar range of
resistance prevalence of 3.2% and 12.5% A. fumigatus
isolates was observed in clinical samples from chronic
pulmonary aspergillosis (CPA) and allergic bron-
chopulmonary aspergillosis (ABPA) patients from Iran
and Kuwait respectively.83,84
Molecular mechanisms of azole resistance in
Candida spp. and Aspergillus spp.
Azoles inhibit enzymes involved in the final stages of
ergosterol biosynthesis, particularly lanosterol 14a-
demethylase. Therefore, sterol precursors – including
methylated sterols – accumulate in the cell, resulting
in cell membrane instability and consequent fungal
growth impairment.85–87
In Candida and Aspergillus, azole resistance appears
to be associated with three major molecular mecha-
nisms, which will be discussed in this review.
Table 3 Primary resistance among Aspergillus species.
Species Invasive disease Resistance profile Section References
A. lentulus Relatively common Primary resistance to AMB,
azoles and varied resistance to CFG
Fumigati [48, 301–304]
A. udagawae Rare Primary resistance to AMB and VRC Fumigati [66, 301, 302, 305, 306]
N. pseudofisheri Rare Varied susceptibility to AMB and
lower susceptibility to azoles
Fumigati [48, 302, 307]
A. fumigatiaffinis Not reported Primary resistance to AMB and lower
resistance to azoles
Fumigati [49]
A. viridinutans Rare Lower susceptibility to AMB and azoles Fumigati [48, 308]
A. flavus Relatively common Primary resistance to AMB and varied
susceptibility to CFG
Flavi [54, 66, 302, 309–313]
A. allilaceus Relatively common Lower susceptibility to AMB and CFG Flavi [302, 314–317]
A. terreus Relatively common Primary resistance to AMB Terrei [66,276,280,318–321]
A. alabamensis Not reported Primary resistance to AMB Terrei [322]
A. niger Rare Varied and lower susceptibility to azoles Nigri [60,310,323–325]
A. calidoustus Rare Primary resistance to AMB and azoles and
varied susceptibility to CFG
Ustis [77,302,326,327]
A. versicolor Rare Varied susceptibility to AMB and lower
susceptibility to azoles
Nidulantes [302,325,328]
A. sydowii Rare Varied susceptibility to AMB and lower
susceptibility to azoles
Nidulantes [60,302,328]
AMB, amphotericin B; CFG, caspofungin; IA, invasive aspergillosis; VRC, voriconazole.
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Decrease in the intracellular drug concentration
The activation of efflux pumps located in the cell
membrane has already been described as an important
mechanism of resistance to antifungal agents in Can-
dida spp. Two different drug efflux systems have been
associated with azole resistance: (i) the ATP-binding
cassette (ABC) protein superfamily, and (ii) the major
facilitator superfamily (MFS) of transporters.
Proteins belonging to the ABC superfamily are pri-
mary transporters that hydrolyse ATP molecules and
are essential for substrate transport. Many ABC trans-
porters with different topologies have been described
in fungal species. In C. albicans, it is believed that there
are 28 types of transporters, and although their role
in azole resistance is not fully understood, two
transporters – Candida drug resistance 1 (CDR1) and
Candida drug resistance 2 (CDR2) – are well
characterised.15,88,89
Sanglard et al. [90] reported that the deletion of
both alleles in the CDR1 gene in C. albicans resulted in
increased intracellular levels of fluconazole. Moreover,
this mutant is hypersensitive to azoles, terbinafine,
amorolfine and several other metabolic inhibitors,
including cycloheximide, brefeldin A and fluphenazine.
Azole-resistant C. albicans isolates showed high CDR2
gene expression levels, even higher than the CDR1
expression levels. Furthermore, the concomitant dele-
tion of CDR1 and CDR2 resulted in increased
susceptibility to azoles.88 Other studies in agreement
with these findings have shown that CDR1 and CDR2
overexpression plays an important role in the azole
resistance phenotype observed in clinical isolates of C.
albicans.91–94
In other Candida species, functional homologues of
CDR1 and CDR2 and other genes encoding ABC trans-
porters have been described and were associated with
drug resistance, including CgCDR1, CgCDR2 (also
known as PDH1) and CgSNQ2 in C. glabrata; CdCDR1
and CdCDR2 in C. dubliniensis and ABC1 in C.
krusei.15,95–102 In C. tropicalis, isolates with in vitro-
induced resistance showed overexpression of
CtCDR1.103 However, this profile was not observed in
clinical isolates of C. tropicalis.104,105 In C. parapsilosis,
Silva et al. [106] reported the increased expression of
CDR1 in isolates with induced resistance to fluconazole
due to the expression of the transcription factor
Ndt80. In C. albicans, Ndt80 is involved in CDR1 regu-
lation. In addition, this transcription factor binds to a
wide range of genes with diverse biological functions,
including other transporter factor, as well as genes
that encode ergosterol biosynthesis enzymes.107,108
The second efflux system associated with azole resis-
tance involves MFS transporters, which transport vari-
ous substrates using the proton gradient generated in
the plasma membrane.89,109 On the basis of in silico
analysis, 95 MFS transporters are believed to occur in
C. albicans. Of these, only the product of the multidrug
Table 4 Rates of triazole resistance in clinical isolates of Aspergillus fumigatus.
Countries Study period Number of samples Resistance rate (%) Methodology References
UK (single centre) 1997–2007 519 6.6 EUCAST [68]
UK (single centre) 2008–2009 230 27.8 EUCAST [69]
The Netherlands (multicentre) 1945–1998 170 1.7 CLSI M38-P [71]
The Netherlands (single centre) 1994–2007 2061 3.1 CLSI M38-A [67]
The Netherlands (multicentre) 2007–2009 1792 4.6 ITZ agar [72]
The Netherlands (multicentre, 8 centres) 2009–2011 921 6.8 4D plates1 [73]
The Netherlands (multicentre) 2010–2013 952 24 EUCAST [74]
Spain (multicentre, 29 centres) 2010–2011 156 0.6 EUCAST [65]
Spain (single centre) 1999–2011 353 4.2 CLSI (M38-A2) [328]
France (single centre) 2006–2009 118 0.8 Etest [329]
France (single centre) 2010–2011 85 8.0 EUCAST [183]
Germany (single centre) 2011–2012 527 3.2 EUCAST [141]
Germany (multicentre) 2010–2013 526 1.1 EUCAST [64]
Germany (multicentre) 2012–2013 27 29.6 Etest [157]
Denmark (single centre) 2007 and 2009 133 4.5 EUCAST [177]
Japan (single centre) 1994–2010 196 11.2 CLSI (M38-A2) [76]
India (single centre) 2005–2010 103 1.9 CLSI (M38-A2) [330]
Iran (single centre) 2003–2009 124 3.2 CLSI M38-A [82]
US (multicentre, 23 centres) 2001–2006 181 0.6 CLSI (M38-A2) [66]
1Triazoles diluted in agar; CLSI, Clinical Laboratory Standard Institute; ITZ, itraconazole; EUCAST, European Committee on Antimicro-
bial Susceptibility Testing.
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resistance 1 (MDR1) gene has been associated with
azole resistance in clinical isolates.15 Importantly,
unlike CDR1 and CDR2 overexpression, which culmi-
nates in resistance to various azoles, MDR1 overex-
pression leads to resistance to fluconazole alone and
does not appear to be associated with cross-resistance
among the azoles.15,89 Different mechanisms are
involved in MDR1 regulation, including the transcrip-
tion factor Mrr1 (multidrug-resistance regulator 1).14
Inactivation of MRR1 in clinical C. albicans strains
blocked MDR1 expression.110 Gain-of-function muta-
tions in MRR1 causing constitutive up-regulation of
MDR1 have been reported in different Candida
species.111–113
Wirsching et al. [114] using gene deletion tech-
niques, found that C. albicans isolates without the
MDR1 gene were extremely susceptible to fluconazole.
In fact, the correlation between MDR1 overexpression
and the fluconazole resistance phenotype has been
previously demonstrated.93,94,115,116
MDR1 homologues genes have been found in differ-
ent species of Candida. Although the CgFLR1 gene con-
fers resistance to fluconazole when expressed in
Saccharomyces cerevisiae, the actual role of this gene in
the resistance phenotype in C. glabrata isolates is not
known.89,97 In C. dubliniensis, the MDR1 gene appears
to play an important role in azole resistance.95,115,117
In C. tropicalis, no association was found between drug
resistance of clinical isolates and MDR1 overexpres-
sion.104,105 In C. parapsilosis, MDR1 expression has
been associated with a fluconazole resistance
phenotype.106,113
Much less is known about the role of efflux pumps in
resistance development in Aspergillus species compared
with the number of studies on resistance in Candida.
Most studies used A. fumigatus as a reference, and genes
coding for efflux transporters are abundant in this spe-
cies. On the basis of in silico analysis, at least 50 genes
encoding ABC transporters and 300 genes encoding
MFS transporters were predicted in the genome of this
fungal species.118,119 Despite the large number of genes
encoding these transporters, little is known about the
association between gene overexpression and triazole
resistance in A. fumigatus. In this species, the overex-
pression of the transporter genes AfuMDR1, AfuMDR2,
AfuMDR3, AfuMDR4 and ATRF is associated with tria-
zole resistance.119,120 The ATRF gene product (AtrF) is
1547 amino acids sequence and has characteristic MDR
motifs.121 The AfuMDR4 gene is also involved in drug
resistance of biofilms produced by A. fumigatus.118 Da
Silva Ferreira et al. [121] reported the expression of five
ABC transporters (abcA–E) and three MFS transporters
(mfsA–C) in response to the in vitro induction of
voriconazole resistance in a clinical, azole susceptible,
isolate. However, to date, the association between these
findings and clinical resistance to azoles has not been
fully elucidated.
Among the transporters characterised in drug-resis-
tant clinical isolates of A. fumigatus, the levels of
CDR1B have been most consistent and prominently
overexpressed. In fact, the mRNA expression levels for
CDR1B were 5- to 30-fold higher in these isolates.
CDR1B deletion also resulted in a 4-fold increase in
the susceptibility to itraconazole in isolates both resis-
tant and susceptible to this drug.122 Of note, the data
available on the effect of efflux pumps on the decrease
in the susceptibility of A. fumigatus to azoles were
obtained from studies on resistance induced in vitro
and not from clinical isolates for which resistance was
acquired during infection of human hosts.122
Changes in the target site of the drug (ERG11/CYP51)
The inhibitory activity of triazoles via changes in the
target site has been described as a frequent cause of
resistance. In this setting, non-synonymous mutations
in ERG11 (CYP51 for Aspergillus) can change the
three-dimensional structure of lanosterol 14a-
demethylase, resulting in decreased affinity of this
molecule to azoles and, consequently, decreased inhibi-
tion of ergosterol biosynthesis.15,123,124
According to Morio et al. [125], more than 140
types of substitutions in the amino acid sequence of
ERG11 have been described in C. albicans. However,
few of these substitutions have been associated with
azole resistance and, when present, may not con-
tribute to the same extent to the development of the
phenotype of resistance to this drug class. To address
this hypothesis, some of these substitutions, including
K143R, S405F, G464S, I471T and R467K, were
described only in azole-resistant isolates, whereas
others, including E266D and V488I, were observed in
isolates both resistant and susceptible to azoles and,
therefore, do not appear to contribute to the resistance
phenotype.125–130
Mutations in ERG11 have also been described in
other species of Candida, including C. dubliniensis, C.
krusei, C. tropicalis and, more recently, C. kefyr and C.
parapsilosis.104,105,113,131–134 Although the primary
mechanism involved in azole resistance appears to be
the expression of efflux pumps, Hull et al. [135]
reported the presence of a non-synonymous mutation
in ERG11 in a clinical C. glabrata isolate with cross-
resistance between azoles and amphotericin B.
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Unlike yeasts, Aspergillus has two distinct genes –
CYP51A and CYP51B – that encode Cyp51. Most
studies indicate that point mutations in the CYP51A
gene in A. fumigatus confer resistance to triazoles and
innate resistance to fluconazole.136 In contrast,
CYP51B is associated with the growth rate and main-
tenance of the fungal cell, but its role in the suscepti-
bility to azoles is still unclear.49 Clinical data suggest
that CYP51A has an important role in regulating the
activity of 14-a-demethylase, whereas CYP51B is a
redundant gene whose expression becomes important
only in the absence of CYP51A.136,137
Specific mutations in CYP51A may confer resis-
tance to one, two or all triazoles, and various muta-
tions in this gene have been described in clinical
isolates and laboratory-generated mutants.63,138 Non-
synonymous point mutations are reported more fre-
quently in this gene, particularly in codons 54, 98,
138, 220, 431, 434 and 448.72,139 Among these
mutants, isolates with changes in codons 98, 138,
431, 434 and 448 generally have the pan-azole
resistance phenotype, i.e. resistance to all azoles.68
Denning et al. [140] evaluated 25 sputum samples
positive for Aspergillus from patients with chronic pul-
monary aspergillosis and allergic bronchopulmonary
aspergillosis and detected mutations in codon M220
in four (16%) samples. Three of the four patients
with this marker experienced treatment failure when
itraconazole and/or posaconazole were used. To date,
more than 30 different point mutations in CYP51A
conferring azole resistance in A. fumigatus have been
identified.141–143
Another type of azole resistance mechanism that
occurs very frequently is a tandem repeat in a 34-bp
sequence in the promoter region (TR34) of the
CYP51A gene. This mechanism, combined with a leu-
cine to histidine substitution at codon 98 (L98H),
resulted in increased CYP51A expression.63,67,144,145
This mutation is probably associated with use of azole
fungicides in agriculture and was first reported in
Europe.67 The same resistance mechanism was subse-
quently reported in clinical and environmental azole-
resistant A. fumigatus from all over the world including
Africa, Americas, Asia, Australia and the Middle
East.12,57,80,146,147 In contrast, more recently few
studies from Japan, described azole resistance in clini-
cal A. fumigatus isolates but interestingly none of them
exhibited TR34/L98H resistance mechanism, instead
several SNPs and novel mutations, F332K and P216L
were reported.148,149 A single centre study from Japan
reported 5.2% azole-resistant isolates harbouring only
G54E/R/W and I266N mutation.76,82
Recently, a novel mechanism of resistance involving
the tandem repeat of a 46-bp sequence (TR46),
together with the substitution of a few amino acids
(Y121F/T289A), was associated with treatment failure
in patients using voriconazole in the Netherlands.73 In
addition to Belgium and the Netherlands, clinical and
environmental isolates carrying the TR46/Y121F/
T289A mutation have been identified in China,
Colombia, Denmark, France, Germany, India, Spain,
Tanzania and US.12,64,150–158 The TR34/L98H muta-
tion induces pan-azole resistance, whereas the TR46/
Y121F/T289A mutation induces high resistance to
voriconazole.73,74,151–156
Hodiamont et al. [159] evaluated a patient with
chronic granulomatous disease and osteomyelitis due
to A. fumigatus and found a mutation associated with
the tandem repeat of a 53-bp sequence in the pro-
moter region of CYP51A in this species. However, this
mutation did not involve any amino acid substitution.
It is of note that the patient received prophylaxis with
itraconazole and that the isolate showed resistance to
itraconazole and voriconazole and lower susceptibility
to posaconazole. This same TR53 has recently been
found in resistant environmental A. fumigatus isolates
from Colombia.158
In fact, not all isolates with increased MIC values
have a mutation in the CYP51A gene, and not every
mutation implies fungal resistance to antifungal
agents.67
Increased production and inhibition of the target
enzyme by the drug
The increased production of ergosterol due to the
increase in the expression of the ERG11 gene (CYP51)
constitutes a common azole-resistance mechanism in
C. albicans and A. fumigatus.92–94,123,160 In C. albicans,
two mechanisms are associated with ERG11 overex-
pression: (i) an increase in the expression of the tran-
scription factor Upc2, which is responsible for
regulating the expression of most genes involved in
ergosterol biosynthesis; and (ii) formation of an
isochromosome with two copies of the left arm of
chromosome 5, where the ERG11 gene is located, or
full duplication of the chromosome.14
The association between increased expression of
ERG11 and azole resistance has also been reported in
C. dubliniensis, C. glabrata, C. krusei, C. parapsilosis and
C. tropicalis.45,105,113,131,161–163
In A. fumigatus, the increased production of ergos-
terol may be associated with the transcriptional
regulation of the CYP51A gene, and this regulation
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may be mediated by both transcription factors and
tandem repeats in the promoter regions. SrbA, a tran-
scriptional regulator belonging to the sterol regulatory
element binding protein (SREBP) family, has important
implications in triazole resistance in Aspergillus.164 The
deletion of the SRBA gene in A. fumigatus induces
hyper susceptibility to azoles and increases fungal sus-
ceptibility to fluconazole. This phenomenon may be
associated with decreased expression of the CYP51A
gene in the absence of SrbA because isolates with
repressed CYP51A also exhibited increased susceptibil-
ity to this drug.136,165,166
Recently, the complete genome sequences of two
inbred isolates of A. fumigatus (one susceptible and one
resistant) isolated from immunocompromised patients
with chronic pulmonary aspergillosis were used to
identify mutations that confer azole resistance. This
study identified several non-synonymous mutations.
However, only the mutation in the transcription factor
associated with the CCAAT-sequence in a subunit of
the HapE complex conferred resistance of this progeny
to azoles by increasing the CYP51A gene expression
levels.167 CCAAT-sequences are present in the promot-
ers of a large number of eukaryotic genes. In general,
they are formed by approximately 50- to 200-bp
sequences upstream of the transcription initiation site
and may occur in any orientation of the gene. These
sequences are attached to different transcription
factors, which can explain the diversity of functions
associated with the modulation of the transcription
levels in eukaryotic cells.168 Coincidentally, the
CCAAT-sequence is present in the promoter of the
CYP51A gene. Therefore, the hapE mutant can induce
the increase in the expression of the CYP51A mRNA,
demonstrating that transcription factors can regulate
the expression of these genes.167 However, to date,
these changes have not yet been described among
resistant clinical isolates.
Risk factors for the development of
candidaemia by fluconazole-resistant
isolates
The first epidemiological studies that assessed the risk
for developing bloodstream infection (BI) due to C.
glabrata and C. krusei, which are intrinsic resistant to
fluconazole, provided clinicians with information nec-
essary for the early detection of patients at risk of
developing IFIs due to fluconazole-resistant Candida
isolates. In these cases, the independent variables asso-
ciated with BI due to C. glabrata included the previous
use of fluconazole or caspofungin, recent exposure to
metronidazole, surgical procedures, the presence of
central venous catheter (CVC) position, cancer,
mechanical ventilation and senescence.169–171 For
infections due to C. krusei, the independent risk factors
included previous exposure to fluconazole or caspo-
fungin, neutropenia, solid tumours, organ transplanta-
tion, splenectomy and use of antibiotics with
antianaerobic coverage.170–172
Over the past few years, an increase in the number of
cases of candidaemia due to fluconazole-resistant iso-
lates belonging to species primarily sensitive to this
drug, including C. parapsilosis and C. tropicalis were
noted.17,18,20–22,26,28,38,44 Several studies have explored
the predisposing factors for the development of candi-
daemia due to fluconazole-resistant Candida species.
In this scenario, Garnacho-Monteiro et al. [173]
observed that neutropenia, chronic kidney disease and
previous exposure to fluconazole were independent risk
factors for the isolation of fluconazole-resistant Candida
isolates. Recently, Cuervo et al. [174], on the basis of
clinical data easily obtained at the bedside, developed
and validated a score that allows for the estimation of
the risk of candidaemia due to fluconazole-non-suscep-
tible (Flu-NS) isolates. The multivariate analysis indi-
cated that the following variables were classified as
risk factors for fluconazole resistance: previous use of
azoles for 3 days, hospitalisation in units with a preva-
lence of candidaemia due to Flu-NS isolates >15%,
and previous history of transplantation.
Risk factors for resistance development in A.
fumigatus worldwide: epidemiological
model in the Netherlands and the UK
High rates of triazole resistance in A. fumigatus were
reported in the Netherlands and in the UK.68 The first
clinical case of resistance to itraconazole was reported
in 1997.175 In 2000, Moore et al. [70,176] tested the
susceptibility of more than 900 isolates to ampho-
tericin B and itraconazole. The percentage of patients
harbouring A. fumigatus isolates resistant to this drug
class increased to 15% in 2007 and to 20% in 2009.
In the Netherlands, azole resistance increased dramati-
cally from 2.5% in 2000, to 4.9% in 2002, to 6.6% in
2004, to 10% in 2009.46 By 2013 in certain centres
resistance rates of up to 15% are found in high risk
haematology patients.75 This trend represents a yearly
increase of 6%, and in this case, the patients were
infected by resistant isolates but without prior expo-
sure to antifungal therapy.62 Therefore, although
higher rates of resistance in A. fumigatus were
described in the Netherlands and the UK (Manchester),
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it is essential to recognise that the mode of resistance
development had distinct determinants in these
countries.
In Manchester, where the National Aspergillosis
Centre is located, the hypothesis of resistance is attrib-
uted to the use of long-term antifungal therapy in
patients with chronic forms of pulmonary aspergillosis,
more specifically, aspergilloma and chronic cavitary
aspergillosis. In the latter case, some researchers sug-
gested the occurrence of microevolution of the fungus
in the lung tissue because both sensitive and resistant
isolates with identical or closely related genotypes
were reported to infect the same patient.177,178
In the Netherlands, the occurrence of triazole resis-
tance in Aspergillus is closely associated with so called
environmental mutations. It is believed that the use of
azoles as fungal pesticides has led to the emergence of
mutations in the CYP51A gene.46,57 From approxi-
mately 30 azole fungicides commonly used in agricul-
ture, seven showed cross-resistance with azoles in
clinical use.79,179 Two resistance mechanisms associ-
ated with point mutations in CYP51A (TR34/L98H and
TR46/Y121F/T289A) have been reported in clinical and
environmental isolates, and the latter were recovered
from patients not exposed to antifungal agents.151–153
An increasing number of cases involving azole-resis-
tant environmental isolates of A. fumigatus have been
documented in Asia and Europe.78,79,83,180 It is sug-
gested that most of the clinical cases of resistance
reported between 2009 and 2011 from Dutch patients
were due to the dissemination of resistant environ-
mental isolates.181 Between 2012 and 2015, other
countries, including Austria, Belgium, Denmark,
France, Germany, Ireland, Poland, Spain, Sweden and
the UK, also reported the identification of clinical
isolates of A. fumigatus harbouring the TR34/L98H
mutation.12,65,141,152,181–183
The wide geographical distribution of the TR34/
L98H mutation has raised questions about the origin
of azole-resistant Aspergillus isolates, including (i) the
geographical migration of resistant conidia carrying
this mutation, (ii) the independent local development
of this mutation and subsequent selection of the TR34/
L98H mutation in unrelated isolates and (iii) the previ-
ous two hypotheses occurring simultaneously.144 To
clarify the origin and dissemination of this genotype,
Camps et al. [181], using molecular markers, evalu-
ated the genetic relationship of 142 European isolates
recovered between 1998 and 2007. The authors noted
that the isolates with the TR34/L98H resistance mech-
anism showed less genetic variation compared with
wild-type susceptible isolates or with those with other
resistance mechanisms. In addition, the crossing of
these isolates indicated that the TR34/L98H isolates
could cross with azole susceptible isolates of different
genetic origins, suggesting that TR34/L98H isolates
could complete their natural sexual cycles. This find-
ing suggests the occurrence of a common ancestry for
the TR34/L98H mechanism.
181
Chowdhary et al. [79] evaluated nine loci in azole-
resistant and susceptible isolates from India and
observed the occurrence of a wide genetic diversity
among environmental and clinical isolates susceptible
to azoles, and these isolates were highly polymorphic.
The azole-resistant isolates harbouring the TR34/L98H
mutation shared the same genotype, indicating clonal
propagation. However, this genotype was not detected
in other isolates from other countries, such as China,
France, Germany and the Netherlands. Therefore, the
authors suggested that the Indian genotype was an
adaptive recombinant progeny derived from the cross-
ing between an azole-resistant isolate (that migrated
into India) and an azole-sensitive isolate (that was
native to India); this crossing underwent mutation
and quickly dispersed to various parts of India.78
Of note, 61% of the global agricultural fungicide
market is concentrated in Western Europe and Asia,
suggesting that the prevalence of the TR34/L98H
mutation in the CYP51A gene is directly associated
with geographical parameters and the indiscriminate
use of these antifungal fungicides.184
With regard to the emerging TR46/Y121F/T289A
mutation, to date, clinical isolates carrying this muta-
tion have been detected in China, Belgium, Denmark,
France, Germany, the Netherlands, Spain and the US,
whereas environmental isolates with this mechanism
have been reported in Belgium, Colombia, France, Ger-
many, India, the Netherlands and Tanzania.12,64,150–
152,157,158,184
At this point, an increased concern about the rapid
spread of isolates harbouring these two mutations
should be underscored because these cases have been
reported in hospitals and homes throughout Eur-
ope.12,73 Furthermore, the exposure of A. fumigatus to
azole fungicides can induce the emergence of novel
resistance mechanisms over time, thereby compromis-
ing the clinical use of azoles in the treatment of dis-
eases associated with Aspergillus.
Rates of echinocandin resistance in Candida
spp. and Aspergillus spp. worldwide
Echinocandins represent the most recent antifungal
class, consisting of three agents – micafungin,
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anidulafungin and caspofungin – that act by inhibiting
cell wall synthesis. Caspofungin was the first
echinocandin approved by the Food and Drug Admin-
istration (FDA) in 2001 in the US, followed by mica-
fungin and anidulafungin, which were approved in
2005 and 2006, respectively, and the three drugs are
available only in parenteral preparations.185–187 Since
their introduction, echinocandins have been widely
used for the treatment and empirical therapy of fungal
infections due to Candida and Aspergillus.188–190
Although echinocandin resistance is still considered
unusual, cases of resistance by using this therapeutic
class have become increasingly frequent.42,191
Recently, Cleveland et al. [192] conducted a surveil-
lance study in two US cities between 2008 and 2013
involving invasive candidiasis in a prospective cohort.
In this series, increases in cases of echinocandin resis-
tance were observed in Atlanta (from 1.2% to 2.9%, a
147% increase) and Baltimore (2% to 3%, a 77%
increase). In addition the authors reported that 44% of
the multidrug-resistant isolates that exhibited an
echinocandin- and fluconazole resistance phenotype
were recovered from patients without prior exposure
to echinocandins, suggesting the occurrence of hori-
zontal transmission of this resistant phenotype.
Although this resistance mechanism remains
uncommon in isolates of C. albicans, C. krusei and C.
tropicalis, echinocandin resistance has become increas-
ingly common among isolates of C. glabrata and other
species such as C. lusitaniae and C. kefyr.42,193
Recently, Alexander et al. [194] reported that in the
US, the resistance rate of C. glabrata isolates increased
from 4.9% to 12.3% between 2001 and 2010. In Eur-
ope, the same trend is observed, although on a smaller
scale. Accordingly, a study reported that the resistance
rate of C. glabrata isolates increased from 0% to 3.1%
between 2004 and 2013 in Denmark.195 It is impor-
tant to mention that the factors associated with the
increased development of resistance in C. glabrata
isolates remain unknown.195
In Latin America, a single case report has demon-
strated clinical and microbiological echinocandin resis-
tance in Candida. Bizerra et al. [196], using sequencing
methodologies for the study of FKS genes and quantifi-
cation of glucan synthesis, reported the occurrence of
a mutation associated with this resistance phenotype
in C. glabrata isolated from a single patient.
To date, little is known about echinocandin resis-
tance in Aspergillus, particularly because susceptibility
tests are not performed routinely and present technical
difficulties and problems associated with reproducibility
and the clinical-in vitro testing correlation.197,198
Because the therapeutic outcome of treatment of
aspergillosis with echinocandins is poorer than with
polyenes and triazoles, the use of echinocandins in
these patients is limited and restricted to cases involv-
ing empirical or combination therapies.189,198,199
Consequently, few cases of secondary resistance of
Aspergillus to this therapeutic class have been reported.
However, non-Aspergillus fumigatus species may exhibit
primary resistance, as is the case in A. lentulus.200,201
Molecular mechanisms of echinocandin
resistance in Candida spp. and Aspergillus
spp.
Echinocandins present predominantly fungicidal activ-
ity against Candida spp. and fungistatic activity against
Aspergillus spp.202–204
Experimental data have shown that the primary
mechanism of action of echinocandins is associated
with inhibition of the synthesis of the fungal cell wall
via inhibition of b-1,3-glucan synthase (Fks1/AfFks1
for Aspergillus fumigatus), which is responsible for the
synthesis of b-1,3-glucans.205 In fungi belonging to
the phylum Ascomycota, the paralogous genes FKS1,
FKS2 and FKS3 are responsible for the synthesis of b-
1,3-glucan synthase. In most species, the FKS1 gene
is more active, whereas FKS2 is expressed in adverse
conditions and only during the sexual cycle and
sporulation.205 The FKS3 gene is involved in the for-
mation of the cell walls of spores.206 In some species,
including C. glabrata, FKS1 and FKS2 are functionally
redundant.207 In Aspergillus spp., only FKS1 has been
described.208 The echinocandin resistance mechanisms
reported in Candida spp. and Aspergillus spp. will be
discussed below.
Mutations in the FKS genes
The main resistance mechanism described for
echinocandins involves the occurrence of mutations in
the FKS1 gene, resulting in conformational changes in
the enzyme encoded by this gene (Fks1), decreased
affinity between echinocandins and Fks1, and the con-
sequent resistance to these compounds.209–212 These
mutations occur in two specific, highly conserved
regions of the FKS1 gene known as hot spot 1 (HS1),
corresponding to positions 641-649 in the amino acid
sequence of the Fks1 protein, and hot spot 2 (HS2),
spanning positions 1345-1365 of the amino acid
sequence.211,213
In C. albicans, among the mutations already
described, the replacement of serine with proline,
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phenylalanine or tyrosine at position 645 has been
described as the most frequent event.14,211,213–215 In
fact, Balashov et al. [209] found that, among 85
caspofungin-resistant isolates of C. albicans, 93% had a
mutation in the serine residue at position 645.
Mutations in FKS1 have been described not only in C.
albicans but also in C. krusei, C. parapsilosis and C. tropi-
calis and, more recently, in C. kefyr.201,210,213,214,216,217
In C. glabrata, in addition to mutations in FKS1,
mutations in the FKS2 gene have been associated with
echinocandin resistance.196,218–221
In contrast to the mutations described for the
Candida species that develop secondary resistance to
echinocandins, isolates of the complexes C. guillier-
mondii and C. parapsilosis develop natural mutations,
not due to exposure to the drug, which explain their
higher MIC values to all echinocandins.222–224 In fact,
the Fks1 coding regions of all members of the C. parap-
silosis complex contain a mutation at position 660 of
the amino acid sequence involving the substitution of
proline with alanine.216 Similarly, it has been reported
that the Fks1 coding regions of all isolates of C. guil-
liermondii contain a substitution at position 642 of the
amino acid sequence.211 Despite the higher MIC
values, various experimental and clinical studies have
demonstrated that these drugs exhibit inhibitory activ-
ity against C. parapsilosis infections. However, their
antifungal activity is only fungistatic and not fungici-
dal, which may explain the higher incidence of persis-
tent candidaemia with C. parapsilosis in patients
treated with echinocandins.225–229
Despite the advances made in the characterisation
of echinocandin resistance mechanisms in Candida,
to date, little is known about the molecular basis of
Aspergillus resistance to these drugs.56 Moreover, few
clinical isolates associated with treatment failure
have been investigated. Arendrup et al. [230] evalu-
ated the echinocandin resistance mechanism of an
isolate of A. fumigatus isolated from a patient with
invasive pulmonary aspergillosis who experienced
treatment failure with caspofungin; this isolate did
not harbour mutations in the AfFKS1 gene;
therefore, the b-1,3-glucan synthase was completely
sensitive in vitro. However, the AfFKS1 gene was
overexpressed, indicating that treatment with caspo-
fungin did not decrease the expression of this gene.
Similarly, Arendrup et al. [231] studied the amplified
DNA of A. fumigatus from liver and lung tissue sam-
ples from a patient with aspergillosis subjected to
long-term therapy with caspofungin, but did not find
any mutations in the sequence of the hot spot
region of AfFKS1.
Because the reports of echinocandin resistance in
clinical isolates are rare, several researchers have
sought in vitro models for the induction of resistance
in the laboratory with the aim of better characterising
the resistance mechanisms associated with these
drugs. Gardiner et al. [232] inserted a site-directed
mutation in AfKS1 consisting of a substitution of
serine with tyrosine at codon 678 (S678Y). This
mutation decreased the susceptibility to caspofungin
16-fold, with a minimum effective concentration
(MEC) of 4 lg/mL. This same study used mini-array
analysis of 220 target genes to evaluate the expression
of relevant genes that could contribute to the decrease
in the susceptibility to caspofungin in mutant isolates.
Their results allowed the identification of (i) increased
expression levels of 28 genes encoding structural com-
ponents of the cell wall (AGS2, CWP1, MCI36), (ii)
enzymes responsible for cell wall biosynthesis (Kre1,
Mci35) and (iii) signal transducers (MAPK, MCI106).
The expression levels of genes encoding proteins
involved in transportation, such as MDR1 and MDR4,
were also increased in this mutant.232
Rocha et al. [233] generated a mutant by the sub-
stitution of serine with proline at codon 678 (S678P)
in AfKS1, and this change was sufficient to confer
resistance to three echinocandins, demonstrating that
the modification in Fks1 is a conserved mechanism in
echinocandin resistance among pathogenic fungi.
Of note are the differences in the in vitro susceptibil-
ity profile to echinocandins between different species of
Aspergillus. For example A. niger exhibited higher MECs
to echinocandins compared with other species, sug-
gesting the occurrence of differences in the cell wall
composition in these fungal species.234 In contrast, A.
lentulus was less susceptible to caspofungin, although
it was apparently susceptible to micafungin and anidu-
lafungin. The analysis of the FKS1 region of this fun-
gal species indicated no polymorphism in the hot spot
region of this gene.56,197 One hypothesis to explain
this phenomenon is the excessive production of glucan
by this species, which could limit the effective concen-
trations of antifungal agents.208
Increase in chitin synthesis
The increase in chitin synthesis has been described as
an important resistance mechanism against
echinocandins. Walker et al. [235] have shown that
the exposure of C. albicans to low levels of echinocan-
dins induces the expression of genes encoding chitin
synthases, increases the concentration of chitin in the
cell wall and consequently decreases the activity of
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echinocandin. Corroborating this hypothesis, Plaine
et al. [236] demonstrated that C. albicans mutants with
higher levels of chitin in the cell wall were resistant to
caspofungin, whereas those with decreased levels of
chitin were very susceptible to this drug.
Increased chitin concentrations after exposure to
echinocandins have also been reported in C. glabrata,
C. guilliermondii, C. krusei, C. parapsilosis and C.
tropicalis.237,238
Risk factors for the development of
candidaemia with echinocandin-resistant
isolates
Although still rare, cases of echinocandin resistance in
clinical isolates of Candida have been increasingly
reported, in particular among C. glabrata isolates.193
Using case–control studies, several authors have
highlighted that prior exposure to echinocandins
results in a higher risk of developing candidaemia due
to the lower susceptibility of these isolates to this class
of antifungal agents.215,239,240 For infections due to C.
glabrata, in addition to the previous exposure to anti-
fungal agents, exposure to total parenteral nutrition
(TPN) has also been reported to be a predisposing fac-
tor.241–243 Recent studies have indicated the develop-
ment of echinocandin resistance after short periods of
exposure to these antifungal agents. In fact, Ruggero
and Topal identified a C. albicans isolate with a FKS1
mutation after 14 days of prophylactic therapy with
micafungin.244
Resistance to amphotericin B
Amphotericin B is an antifungal agent belonging to
the class of polyenes which are natural antifungal
compounds produced by species of the genus Strepto-
myces. Since the 1950s until the discovery of azoles,
standard therapy for IFIs involved the use of ampho-
tericin B. Because of its broad spectrum of activity
against yeasts, filamentous and dimorphic fungi and
its fungicidal activity, amphotericin B based drugs are
still considered the gold standard for the treatment of
most fungal infections, particularly in cases of severe
IFI, when a quick response is required.89,200,245–247
The classical mechanism of action of amphotericin
B involves the irreversible binding to ergosterol present
in the plasma membranes of fungal cells, resulting in
the formation of pores in the cell membrane, with loss
of K+ and Na+ ions, which leads to impairment of the
cellular osmotic balance and consequent cell
death.89,248,249 Furthermore, recent findings have
shown that exposure to amphotericin B induces the
production and accumulation of reactive oxygen spe-
cies, which eventually causes cell death.250,251
Although amphotericin B has a broad spectrum of
activity, this antifungal drug is highly toxic to the
host. Nephrotoxicity is the major side-effect, which has
limited its clinical use.188,252–256 To decrease drug tox-
icity, lipid formulations have been developed which
are currently first choice of treatment of IFIs.257–261
Secondary resistance to amphotericin B is rare
among isolates of Candida spp., but some cases of resis-
tance have been reported.135,262–267 Several studies
have shown resistance of C. lusitaniae to this drug.
Although these studies reported that C. lusitaniae iso-
lates have low rates of resistance in vitro, this species
seems to develop secondary resistance during
treatment with amphotericin B, and several cases of
therapeutic failure are on record.267–274
Similar to Candida, secondary resistance to ampho-
tericin B has not been observed in Aspergillus,
although some patients experienced treatment failure
when using this drug.262,263,275 However, primary
resistance to amphotericin B has been reported among
isolates of A. flavus, A. lentulus, A. terreus and A.
ustus.48,53,276–280
Previous studies have also shown that isolates of A.
flavus exhibit higher MIC values to amphotericin B
compared with isolates belonging to the section
Fumigati.65,199,276,277,279,281
Hadrich et al. [277] evaluated the in vitro suscepti-
bility to amphotericin B of 37 A. flavus isolates recov-
ered from 14 patients with haematological
malignancies, of which 13 were treated with ampho-
tericin B deoxycholate. Of the total isolates evaluated,
84% (N = 31) exhibited resistance to this drug
in vitro. Among the patients infected with resistant iso-
lates, nine were treated with amphotericin B, and 88%
(N = 7) died.277 Similar results were observed by Lass-
Fl€orl et al. [281], who compared the in vitro suscepti-
bility to amphotericin B in strains of A. flavus with
clinical outcome of patients undergoing bone narrow
transplantation. In this study, 12 A. flavus sensu lato
isolates were evaluated. Only patients infected with
susceptible isolates (MIC to AMB <2 lg/mL, N = 4)
survived, whereas those infected with resistant isolates
(CIM to AMB ≥2 lg/mL, N = 8) died.281
Alastruey-Izquierdo et al. [65] evaluated 280 clini-
cal isolates of Aspergillus from 29 Spanish hospitals
and reported a rate of resistance to amphotericin B of
10.8%. In this series, four of 27 (14.8%) A. flavus iso-
lates and seven of 26 (27%) A. terreus isolates were
resistant to this drug. In Brazil, Goncalves et al. [54]
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observed a high rate of resistance (49%) to ampho-
tericin B in a series consisting of 77 clinical isolates
belonging to the section Flavi. Likewise studies from
India show high amphotericin B MICs in 31 out of 37
isolates (84%) [277]. However, the genetic mecha-
nisms responsible for acquired resistance to ampho-
tericin B have not been elucidated. Some studies have
indicated that mutations in the genes involved in the
biosynthetic pathway of ergosterol (ERG), including
ERG2, ERG3, ERG5, ERG6 and ERG11, may lead to
decreased concentration of ergosterol and the forma-
tion of intermediate sterols in the fungal cell mem-
brane.104,282–286 These quantitative and qualitative
changes in plasma membrane sterols decrease the
affinity of amphotericin B for its target sites and con-
stitute the major mechanisms of resistance of Candida
isolates to this drug.
Although most of the data related to resistance mech-
anisms for amphotericin B have been observed in trials
with yeast, Chamilos and Kontoyiannis thoroughly
reviewed these mechanisms in Aspergillus. These
authors reported that these mechanisms can be attribu-
ted to two phenomena: (i) a decreased concentration of
membrane ergosterol via mutations in the biosynthetic
pathway of ergosterol and/or prior exposure to triazoles,
and (ii) increased production of reducing enzymes (e.g.
catalase), which confer resistance to oxidative stress
and can also act as oxidising agents.287
Although A. terreus is the best studied species, its
intrinsic mechanism of resistance to amphotericin B is
not fully elucidated but has been attributed to the high
expression levels of catalase, an enzyme that causes
damage to the fungal cell membrane via generation of
reactive oxygen species.288 A recent study showed
that application of pro-oxidants significantly affects
amphotericin B efficacy by rendering resistant isolates
more susceptible to this drug which was also con-
firmed in vivo in a Galleria model.289
Conclusions
Over the past few years, the significant increase in the
use of antifungal agents for the treatment of candidia-
sis and invasive aspergillosis has resulted in the emer-
gence of resistant clinical isolates, particularly against
triazoles and echinocandins. In addition, a recent
emergence of fluconazole resistance among isolates
that were primarily sensitive to this drug, including C.
parapsilosis and C. tropicalis has been noted. For
echinocandins, despite the low resistance rates, the
occurrence of isolates with lower susceptibility to this
drug has been increasingly reported, particularly
among C. glabrata isolates.
Therefore, we highlight the need to conduct antifun-
gal resistance surveillance studies using clinical iso-
lates of Candida and Aspergillus in different
geographical regions and monitoring of the infection
rates in distinct population groups with the aims of
early detection of resistance to these drugs and imple-
mentation of efficient policies for infection control and
treatment.
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